Loading…

Antiviral activity of angelicin against gammaherpesviruses

•A cell-based antiviral screening was performed against MHV-68.•Angelicin efficiently inhibited MHV-68 replication following the virus entry.•The IC50 of angelicin was estimated to be 5.39μg/ml (28.95μM).•Angelicin also blocked EBV and KSHV lytic replication.•Other related compounds exhibited antivi...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2013-10, Vol.100 (1), p.75-83
Main Authors: Cho, Hye-Jeong, Jeong, Seon-Gyeong, Park, Ji-Eun, Han, Jin-Ah, Kang, Hye-Ri, Lee, Dongho, Song, Moon Jung
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A cell-based antiviral screening was performed against MHV-68.•Angelicin efficiently inhibited MHV-68 replication following the virus entry.•The IC50 of angelicin was estimated to be 5.39μg/ml (28.95μM).•Angelicin also blocked EBV and KSHV lytic replication.•Other related compounds exhibited antiviral effect against gammaherpesviruses. Human gammaherpesviruses including Epstein–Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) are important pathogens as they persist in the host and cause various malignancies. However, few antiviral drugs are available to efficiently control gammaherpesvirus replication. Here we identified the antiviral activity of angelicin against murine gammaherpesvirus 68 (MHV-68), genetically and biologically related to human gammaherpesviruses. Angelicin, a furocoumarin naturally occurring tricyclic aromatic compound, efficiently inhibited lytic replication of MHV-68 in a dose-dependent manner following the virus entry. The IC50 of angelicin antiviral activity was estimated to be 28.95μM, while the CC50 of angelicin was higher than 2600μM. Furthermore, incubation with angelicin efficiently inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced lytic replication of human gammaherpresviruses in both EBV- and KSHV-infected cells. Taken together, these results suggest that MHV-68 can be a useful tool to screen novel antiviral agents against human gammaherepsviruses and that angelicin may provide a lead structure for the development of antiviral drug against gammaherpesviruses.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2013.07.009